Comparative study between different pharmaco-therapeutic agents used for the treatment of patients with benign prostatic hyperplasia

ABSTRACT

A total of 126 patients were included in this study. The mean age of patients was 59.7 +/- 9.6 years [range 48-89 years]. All patients had symptoms suggestive of benign prostatic hyperplasia [BPH]. All patients were treated medically for six months with different pharmacological agents Doxazosin [41], finasteride [33], combined doxazosin with finastride [22] and Seronea repens extract [30]. A control group, given placebo, included 20 patients who were age- matched and had obstructive lower urinary tract symptoms proved to be caused by BPH. All patients in both study and control groups were followed up for a period at least six months. Symptomatic evaluation, sonography and uroflowmetry were done to measure the efficacy of these agents. From the results obtained, it was concluded that, doxazosin is the most rapid single agent to improve the symptoms of BPH. Finasteride relieves both symptoms and prostate size after six months. Combined therapy is more effective and rapid than treatment with either doxazosin or finasteride alone. Seronea repens extract has a clinical efficacy similar to that of finasteride on both symptoms of BPH and reduction in the prostate size